Picture loading failed.

Pre-Made Pavunalimab biosimilar, Bispecific Mixed mAb and scFv, Anti-LAG3;CTLA4/CTLA-4 Antibody: Anti-CD223;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-432-1mg 1mg Inquiry
GMP-Bios-ab-432-10mg 10mg Inquiry
GMP-Bios-ab-432-100mg 100mg Inquiry
GMP-Bios-ab-432-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Pavunalimab biosimilar, Bispecific Mixed mAb and scFv, Anti-LAG3;CTLA4/CTLA-4 Antibody: Anti-CD223;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
INN Name Pavunalimab
TargetLAG3;CTLA-4
FormatBispecific Mixed mAb and scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2020
Year Recommendedna
CompaniesXencor
Conditions Approvedna
Conditions ActiveSolid tumours
Conditions Discontinuedna
Development Techna